ICIs like PD-1/PD-L1 and CTLA-4 inhibitors have been particularly effective in improving survival outcomes in several cancers, including HCC, melanoma, and non-small cell lung cancer (NSCLC) [113,114,115]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.